Why Are Monoclonal Antibodies the First Prime Targets for Animal-Free Testing at FDA?
Read here
In Monumental Declaration, NIH Follows FDA and Says Agency Will Turn Away from Animal Testing
Read here
FDA Announcement on Phasing Out Animal Testing a Remarkable Turnaround
Read here
U.S. Senate Passes FDA Modernization Act 3.0, Sends Urgent Measure to House for Final Action
Read here
Is DOGE the Swan Song for Animal Testing?
Read here

Latest News

Tell your legislators

to support the FDA Modernization Act 3.0 to stop the FDA from causing the needless torment of beagles, primates and other animals in new drug approvals.
Here

FDA Must Take Immediate Steps to Implement the
FDA Modernization Act 3.0

The Food Drug and Cosmetics Act was amended in 2022 to allow for human-relevant nonanimal test methods, lifting the mandate for animal testing.

The current state

Outdated Regulations

FDA must initiate rulemaking so outdated regulations comport with the revised statute and Congressional intent.

Deliberate Ambiguity at FDA

Current FDA programs to evaluate and accept nonanimal test methods are vague, ineffective, top-heavy, and lack transparency, failing to set up the agency or drug developers for success. FDA must end its deliberate ambiguity practice regarding the use of animals in preclinical research.

the path forward

Regulatory Clarity

FDA must create a clear pathway for regulatory acceptance of nonanimal test methods.

Break the status quo

FDA must act expeditiously to change the drug development paradigm as Congress intended. Otherwise, the 90 to 95% failure rate in clinical trials of drugs that pass animal tests for safety and efficacy fail in human trials will continue.

Read our Fact Sheet

on the FDA Modernization Act 3.0

HERE

Center for a Humane Economy is the first non-profit animal welfare organization that focuses on influencing the conduct of corporations to forge a humane economic order.

Donate
Facebook
Contact Us

© 2025 Center for a Humane Economy | All Rights Reserved